Akhilesh’s hands stained with blood of riot victims, claims Yogi

Agencies
May 23, 2018

Kairana , MAY 23: As campaigning in the Lok Sabha bye-election in this communally sensitive constituency picks up, Uttar Pradesh Chief Minister Yogi Adityanath said his predecessor Akhilesh Yadav’s hands were stained with the blood of victims of the Muzaffarnagar riots.

“The SP chief doesn’t have the courage to come here and campaign. His hands are stained with the blood of Muzaffarnagar riot victims," he said in a meeting at Ambheta in Saharanpur district yesterday.

The chief minister’s reference was to the Hindu-Muslim riots in adjoining Muzaffarnagar district in 2013, when several Muslim families fled their homes.

In 2016, there was communal tension in Shamli district’s Kairana block with allegations that the threatened Hindus were leaving their homes.

Attacking the SP government, which was in power then, Adityanath said, “During the previous government, there were no jobs for the youngsters and only a specific community got jobs.”

“We have adopted the practice of taking people from every caste and religion along with us,” he said.

The May-28 polls are being held to fill the Kairana Lok Sabha seat, spread over Saharanpur and Shamli districts, which fell vacant after the death of BJP’s Hukum Singh.

His daughter Mriganka Singh is now the BJP candidate, pitted against Rashtriya Lok Dal’s Tabassum Hasan who is backed by the opposition, including Akhilesh Yadav’s Samajwadi Party.

The opposition hopes to repeat the shock defeat its joint candidates delivered to the BJP recently in the bypolls in Gorakhpur and Phulpur in Uttar Pradesh.

Attacking the opposition, Adityanath said, “During elections they get united, because they have nothing to do with development and good governance.”

“All of them are talking about getting united, but the unity is not visible. The SP president is yet to be seen here, as people will question him about Muzaffarnagar riots if he comes here,” he said.

“Today, it is not the traders, farmers or youngsters who are undertaking an exodus. It is the criminals who are doing so or the SP is doing so,” he said.

The chief minister said the state, which had earlier earned disrepute due to casteism and family politics, now has an agenda revolving around farmers, traders and the youth.

“The BJP will not allow any injustice to happen to the farmers. A victory for the BJP means a victory for prosperity and development,” he said.

Also out campaigning today, UP minister Laxmi Narayan Chaudhary said a BJP win in Kairana, will avenge the loss of Gorakhpur and Phulpur.

“The revenge for the party’s defeat in the bye-elections held in Gorakhpur and Phulpur will come from Kairana. This is no ordinary election,” Chaudhary said at a meeting in Shamli’s Bhaiswal village.

“The entire reputation of western UP is at stake, and it is a curtain-raiser for the 2019 Lok Sabha polls,” he added.

He said Mriganka Singh’s victory will be a true tribute to her father who had worked hard to ensure reservation for the Jats.

“A farmer wants a leader who is honest and is of good character. These were the qualities of Chaudhary Charan Singh. And today, both these qualities can be seen in Prime Minister Narendra Modi and UP Chief Minister Yogi Adityanath,” he said.

During the meeting, a farmer sought the minister's comment on the delay in paying farmers who had sold sugarcane to the mills.

The minister said the dues accumulated from the time of the past governments had been paid out, and the rest will be settled soon.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 5,2020

New Delhi, Mar 5: A Delhi court Thursday issued fresh death warrants for execution of the four convicts in the Nirbhaya gang rape and murder case for March 20 at 5.30 am.

Additional Sessions Judge Dharmendra Rana fixed March 20 as the new date of execution after it was told by the Delhi government that the convicts have exhausted all their legal remedies.

The lawyer for the four death row convicts also told the court that there was no legal impediment for the court to proceed in fixing the date of execution.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed Covid-19 vaccine candidate in the country.

Government officials said that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC) on Covid-19.

"The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said.

"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said.

As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, 'Covishield', on healthy adults in India,  the officials said.

Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.

The officials said that the SII had submitted a revised proposal on Wednesday after the SEC on July 28, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information.

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India.

According to the revised proposal by the SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.

"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of 'Covishield' on healthy Indian adults," the official said.

The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for Covid-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine. 

Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed that it has an acceptable safety profile and homologous boosting increased antibody response, sources had said.

To introduce the vaccine, SII, the world's largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 27,2020

New Delhi, Apr 27: A private hospital here claimed that a coronavirus patient, who was administered plasma therapy for the first time in the facility, was discharged on Sunday after being completely cured.

The 49-year-old man had tested positive for COVID-19 on April 4 and was admitted to Max Hospital, Saket, it said in a statement.

As his condition deteriorated, he was put on ventilator support on April 8, the hospital added.

When the patient showed no signs of improvement, his family requested for administration of plasma therapy on compassionate grounds, it said, adding that the family arranged a donor for extracting plasma.

The patient was administered fresh plasma as a treatment modality as a side-line to standard treatment protocols on the night of April 14, the statement said.

Subsequently, the patient showed improvement and by the fourth day, was weaned off ventilator support and continued on supplementary oxygen. He was shifted to a room with round-the-clock monitoring on Monday after testing negative twice within 24 hours, it said.

He has now fully recovered and was discharged, the hospital said, adding that he will stay at home for another two weeks.

Group medical director of Max Healthcare and senior director of the Institute of Internal Medicine Dr Sandeep Budhiraja said, "We can say that plasma therapy could have worked as a catalyst in speeding up his recovery. We cannot attribute 100 per cent recovery to plasma therapy only, as there are multiple factors which carved his path to recovery."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.